125 related articles for article (PubMed ID: 11060733)
1. Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock.
Eriksson M; Basu S; Larsson A; Mattsson C; Eriksson O; Kiiski R; Nordgren A
Expert Opin Investig Drugs; 2000 May; 9(5):1129-37. PubMed ID: 11060733
[TBL] [Abstract][Full Text] [Related]
2. Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig.
Eriksson M; Larsson A; Saldeen T; Mattsson C
Thromb Haemost; 1998 Dec; 80(6):1022-6. PubMed ID: 9869178
[TBL] [Abstract][Full Text] [Related]
3. Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs.
Eriksson M; Saldeen T; Mattsson C; Larsson A
Acta Anaesthesiol Scand; 2000 Jan; 44(1):24-31. PubMed ID: 10669267
[TBL] [Abstract][Full Text] [Related]
4. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H
Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334
[TBL] [Abstract][Full Text] [Related]
5. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
Elg M; Gustafsson D
Thromb Res; 2006; 117(4):429-37. PubMed ID: 15869787
[TBL] [Abstract][Full Text] [Related]
6. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
[TBL] [Abstract][Full Text] [Related]
7. Direct thrombin inhibitor prevents delayed graft function in a porcine model of renal transplantation.
Giraud S; Thuillier R; Belliard A; Hebrard W; Nadeau C; Milin S; Goujon JM; Manguy E; Mauco G; Hauet T; Macchi L
Transplantation; 2009 Jun; 87(11):1636-44. PubMed ID: 19502954
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
Furugohri T; Morishima Y
Thromb Res; 2015 Sep; 136(3):658-62. PubMed ID: 26188924
[TBL] [Abstract][Full Text] [Related]
9. Effect of low and high dose melagatran and other antithrombotic drugs on platelet aggregation.
Soslau G; Ando A; Floyd L; Hong T; Mathew L; Yen Y
J Thromb Thrombolysis; 2008 Apr; 25(2):198-203. PubMed ID: 17710375
[TBL] [Abstract][Full Text] [Related]
10. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
Mehta JL; Chen L; Nichols WW; Mattsson C; Gustafsson D; Saldeen TG
J Cardiovasc Pharmacol; 1998 Mar; 31(3):345-51. PubMed ID: 9514177
[TBL] [Abstract][Full Text] [Related]
11. Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats.
Furugohri T; Fukuda T; Tsuji N; Kita A; Morishima Y; Shibano T
Eur J Pharmacol; 2012 Jul; 686(1-3):74-80. PubMed ID: 22546231
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
Fager G; Cullberg M; Eriksson-Lepkowska M; Frison L; Eriksson UG
Eur J Clin Pharmacol; 2003 Aug; 59(4):283-9. PubMed ID: 12845508
[TBL] [Abstract][Full Text] [Related]
13. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC; Perry CM; Faulds D
Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
[TBL] [Abstract][Full Text] [Related]
14. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
[TBL] [Abstract][Full Text] [Related]
15. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
16. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Johansson LC; Frison L; Logren U; Fager G; Gustafsson D; Eriksson UG
Clin Pharmacokinet; 2003; 42(4):381-92. PubMed ID: 12648028
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation.
Ozmen L; Ekdahl KN; Elgue G; Larsson R; Korsgren O; Nilsson B
Diabetes; 2002 Jun; 51(6):1779-84. PubMed ID: 12031965
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
[TBL] [Abstract][Full Text] [Related]
19. The direct thrombin inhibitor melagatran counteracts endotoxin-induced endothelial leukocyte adherence and microvascular leakage in the rat mesentery. Rationale for the treatment of inflammatory disorders beyond sepsis?
Leithäuser B; Fassbender M; Eickhoff M; Elg M; Eichner G; Matthias FR
Clin Hemorheol Microcirc; 2007; 36(4):277-89. PubMed ID: 17502698
[TBL] [Abstract][Full Text] [Related]
20. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
Gustafsson D; Nyström J; Carlsson S; Bredberg U; Eriksson U; Gyzander E; Elg M; Antonsson T; Hoffmann K; Ungell A; Sörensen H; Någård S; Abrahamsson A; Bylund R
Thromb Res; 2001 Feb; 101(3):171-81. PubMed ID: 11228340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
